Kinoxis Therapeutics is a clinical stage biotechnology company developing compounds to restore normal social functioning by rebalancing activity in malfunctioning social pathways in the brain. The company focuses on treatments for social dysfunction and substance use disorders.

Kinoxis Therapeutics

Kinoxis Therapeutics is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders. Kinoxis’ development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney.  Kinoxis is backed by Uniseed, Australia’s longest running venture fund, and a consortium of sophisticated investors, and secured funding from the US National Institutes of Health National Institute on Drug Abuse for the development of its lead compound to mitigate opioid withdrawal symptoms.

Kinoxis’ lead candidate (KNX100) is being developed for the mitigation of opioid withdrawal symptoms. KNX100 has a novel, undisclosed mechanism of action and has completed a Phase I clinical study.  The company is also exploring other indications for KNX100, as promising preclinical results have been achieved in animal models of cocaine, methamphetamine, nicotine, and alcohol use disorders, as well as models of agitation and aggression.

Kinoxis’ second series of compounds target the oxytocin receptor, through either selective partial agonism or positive allosteric modulation. The brain oxytocin system has been identified as perhaps the most important molecular target for regulating social behaviour and is therefore a major target of interest for treating a wide range of mental disorders. The development of these compounds will be focused on treating conditions that feature social dysfunction as a core symptom, such as neurodevelopmental disorders (including autism spectrum disorder) social anxiety disorder, dementia (including Alzheimer’s disease), and schizophrenia.

National Institutes of Health

Uniseed Ventures

Stoic VC

Kinoxis Therapeutics Pty Ltd

Kinoxis Therapeutics Pty Ltd is pleased to announce the successful completion of a Series B round of capital raise. A total of $14.5 million funding has been raised through this round, led by key investors Uniseed, UniSuper, University of Sydney, Stoic Venture Capital, Avicella Capital, as well as a number of sophisticated investors.
 
The funds raised will be used to support Phase 2 programs for Kinoxis’ lead drug candidate, KNX100, which addresses behavioural and psychological symptoms across multiple indications, including agitation and aggression in dementia and several substance use disorders.
 
One of the supported programs is CARES-X, a phase 2 clinical study commencing this month. First of its kind in Australia, CARES-X will be conducted across 8 sites with 60 patients, examining the safety, tolerability and efficacy of KNX100 when used as a treatment of agitation in dementia patients.
 
Agitation and aggression in dementia not only have a profound impact on caregivers, but also are often the driver for the transition to assisted living facilities, resulting in a significant economic burden to the public healthcare system. Commenting on the fundraise and the CARES-X study, Kinoxis CEO Hugh Alsop said:” “This injection of funding comes at an important time. We are targeting a significant unmet treatment need for dementia patients, potentially broadening the options for them to maintain a higher quality of life. This is a new and highly promising area of development for KNX100, and we are grateful to have had the strong support from our major investors.”
 
Thanks also to Lis Boyce at Piper Alderman and the team at Bio101 for their support through this round.
 
For more details on the Series B fund raise and the CARES-X study, read the full press release via this link: https://lnkd.in/gw9Htpem

#AgitationinDementia #SubstanceUseDisorder #SeriesB #BiotechInvestment

Kinoxis Therapeutics Pty Ltd is pleased to share that our CEO, Hugh Alsop has been announced as the inaugural recipient of the CEO of the Year award at The Brooker Prize gala.
 
The CEO of the Year award recognises individuals who have made a significant commercial, educational, member-driven or research-based contribution to their organisation or the sector. Thank you Brooker Consulting for this prestigious acknowledgment of Hugh’s contribution to the biotech and life sciences industry. 

As seen in this photo: John Kurek, Investor Director at Uniseed and Dr Rachel C., Principal of Brooker Consulting with Kinoxis CEO, Hugh Alsop. 
 
#leadershipaward #biotech #lifesciences

Kinoxis Therapeutics Pty Ltd CEO Hugh Alsop presenting at #BIO2024 on our clinical stage programs exploring KNX100 for treating agitation and aggression in dementia and substance use disorders

Excited to the share the Kinoxis Therapeutics story at the BIO International Convention in San Diego next week. Join me for my presentation on Wednesday, June 5 at 4:00 PM in Company Presentation Theater 4. See you there. #BIO2024 Kinoxis Therapeutics Pty Ltd

I really enjoyed participating in the session on Alcohol and opioids: overdose, stress, and treatment this morning at the International Drug & Alcohol Research Society Meeting in Rio, where I spoke about the Kinoxis Therapeutics Pty Ltd program developing the clinical stage KNX100 compound for the treatment of substance use disorders.

I recently attended the College on Problems of Drug Dependence (CPDD) Conference in lovely Montreal, Canada. With drug overdoses claiming a life every five minutes in the US alone, the work of the CPDD organization is more critical than ever.

Key discussions at the conference included the importance of addressing polysubstance use and the urgent need for harm reduction strategies. Innovative therapies in development were also highlighted, along with a focused discussion on drug craving—a major factor in the cycle of substance use disorders and a key contributor to relapse. By effectively treating drug cravings, we could reduce the risk of relapse to drug taking. 

👩‍🔬 At Kinoxis Therapeutics Pty Ltd, we are making significant strides in the field of substance use disorders. 

#CPDD2024 #DrugDependence #SubstanceUseDisorders #AddictionResearch #Montreal #Biotech

Metric
Company Name	Kinoxis Therapeutics
Symbol
MSH ID	COM:KINOXISTHERAPEUTICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	AU
Stage
Employee Count	16
Website	kinoxistherapeutics.com
LinkedIn	kinoxis-therapeutics-pty-ltd
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

KINO

COM:KINOXISTHERAPEUTICS

Kinoxis Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue